Company: BIAF
Filing Date: 2025-09-24
Form Type: S-1
Source: 0001493152-25-014730
Chunk: 9

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-09-24
Form: S-1
Chunk 9
---
 we filed with
the Secretary of State of the State of Delaware a certificate of amendment to our certificate of incorporation to effect a one-for-thirty
(1-for-30) reverse split of our issued and outstanding shares of Common Stock. The Reverse Stock Split became effective as of 4:01 p.m.
Eastern Time on September 18, 2025, and our Common Stock began trading on a split-adjusted basis when Nasdaq opened on September 19,
2025. All share and per share information in this prospectus (other than in the historical financial statements incorporated herein by
reference) has been adjusted to reflect the reverse stock split.

Corporate Information

We were incorporated in the State of Delaware on March 26, 2014. Our principal executive office is located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217, and our telephone number at that address is (210) 698-5334. Our website address is https://www.bioaffinitytech.com/. Information contained on or that can be accessed through our website is not incorporated by reference into this prospectus. Investors should not consider any such information to be part of this prospectus.

Implications of Being an Emerging Growth Company and a Smaller Reporting Company

We qualify as an “emerging growth company” (an “EGC”) as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As an EGC, for up to five years, we may elect to take advantage of certain specified exemptions from reporting and other regulatory requirements that are otherwise generally applicable to public companies. For example, these exemptions would allow us to:

| ● | present                                                                                                                    
 two, rather than three, years of audited financial statements with correspondingly reduced disclosure in the “Management’s 
 Discussion and Analysis of Financial Condition and Results of Operations” section (the “MD&A”) of this prospectus;         |
| ● | defer                                                                                                                      
 the auditor attestation requirement on the effectiveness of our system of internal control over financial reporting;       |
| ● | make                                                                                                                       
 reduced disclosures about our executive compensation arrangements; and                                                     |
| ● | forego                                                                                                                     
 the adoption of new or revised financial accounting standards until they would be applicable to private companies.         |

Certain of these reduced reporting requirements and exemptions were already available to us due to the fact that we also qualify as a “smaller reporting company” under SEC rules. For instance, smaller reporting